Meta-Analisis pengaruh faktor daya dukung etiologi sirosis terhadap keberhasilan curcumin sebagai terapi

Authors

DOI:

https://doi.org/10.30989/mik.v11i3.785

Keywords:

Chirrosis, Curcumin, Terapi

Abstract

Background: Cirrhosis is a liver disease that affects 20-30% of people in Indonesia. The etiologic of cirrhosis include autoimmune, hepatitis B, portal vein thrombosis, and alcoholism. The existence of etiological factors may but has not been proven to, influence the success of curcumin therapy.
Objective: This meta-analysis examines the research to show how etiological variables might affect cirrhotic patients' response to curcumin treatment.
Methods: The searching terms "curcuma," "curcumin," and "cirrhosis" were used to find articles in databases. Beginning on January 1, 2020, through August 31, 2022, search data for articles was collected. The article search procedure complies with PRISMA chart requirements.
Results: Overall effect size between treatment groups vs. placebo on autoimmune factor (Ai) namely P= 1.09 (95% CI= 0.44 – 2.74); hepatitis B (HpB) namely P=0.88 (95% CI= 0.25 – 3.08); portal vein thrombosis (TVP) ie P=0.65 (95% CI= 0.14 – 2.99); alcoholic (Alk) namely P = 0.28 (95% CI = 0.04 – 1.77). This demonstrates how the HpB, TVP, and Alk variables have an impact on both groups but not the Ai factor.
Conclusion: The etiological variables HpB, TVP, and Alk may affect how well curcumin treatment for cirrhosis works.

Author Biographies

Winnie Nirmala Santosa, Fakultas Kedokteran, Universitas Surabaya

Jalan Raya Kalirungkut, Surabaya – 60293, Indonesia

Dwi Martha Nur Aditya, Fakultas Kedokteran, Universitas Surabaya

Jalan Raya Kalirungkut, Surabaya – 60293, Indonesia

References

Roehlen N, Crouchet E, Baumert TF. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells [Internet]. 2020 Apr 3;9(4):875. Available from: https://www.mdpi.com/2073-4409/9/4/875 doi: 10.3390/cells9040875

Wong T, Dang K, Ladhani S, Singal AK, Wong RJ. Prevalence of Alcoholic Fatty Liver Disease Among Adults in the United States, 2001-2016. JAMA [Internet]. 2019 May 7;321(17):1723. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2019.2276 doi: 10.1001/jama.2019.2276

Muljono DH, Wijayadi T, Sjahril R. Hepatitis B Virus Infection among Health Care Workers in Indonesia. Euroasian J Hepato-Gastroenterology [Internet]. 2018 Jun 1;8(1):88–92. Available from: https://www.ejohg.com/doi/10.5005/jp-journals-10018-1269 doi: 10.5005/jp-journals-10018-1269

Aydin MM, Akcali KC. Liver fibrosis. Turkish J Gastroenterol [Internet]. 2018 Jan 31;29(1):14–21. Available from: https://www.turkjgastroenterol.org/en/liver-fibrosis-135206 doi: 10.5152/tjg.2018.17330

Berumen J, Baglieri J, Kisseleva T, Mekeel K. Liver fibrosis: Pathophysiology and clinical implications. WIREs Mech Dis [Internet]. 2021 Jan 26;13(1). Available from: https://onlinelibrary.wiley.com/doi/10.1002/wsbm.1499 doi: 10.1002/wsbm.1499

Parola M, Pinzani M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med [Internet]. 2019 Feb;65:37–55. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0098299718300700 doi: 10.1016/j.mam.2018.09.002

Lai M, Afdhal NH. Liver Fibrosis Determination. Gastroenterol Clin North Am [Internet]. 2019 Jun;48(2):281–9. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0889855319300032 doi: 10.1016/j.gtc.2019.02.002

Campana L, Iredale J. Regression of Liver Fibrosis. Semin Liver Dis [Internet]. 2017 Feb 15;37(01):001–10. Available from: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0036-1597816 doi: 10.1055/s-0036-1597816

Irvine KM, Ratnasekera I, Powell EE, Hume DA. Causes and Consequences of Innate Immune Dysfunction in Cirrhosis. Front Immunol [Internet]. 2019 Feb 25;10. Available from: https://www.frontiersin.org/article/10.3389/fimmu.2019.00293/full doi: 10.3389/fimmu.2019.00293

Smith A, Baumgartner K, Bositis C. Cirrhosis: Diagnosis and Management. Am Fam Physician [Internet]. 2019;100(12):759–70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31845776

Kotha RR, Luthria DL. Curcumin: Biological, Pharmaceutical, Nutraceutical, and Analytical Aspects. Molecules [Internet]. 2019 Aug 13;24(16):2930. Available from: https://www.mdpi.com/1420-3049/24/16/2930 doi: 10.3390/molecules24162930

Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. The Essential Medicinal Chemistry of Curcumin. J Med Chem [Internet]. 2017 Mar 9;60(5):1620–37. Available from: https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00975 doi: 10.1021/acs.jmedchem.6b00975

Zia A, Farkhondeh T, Pourbagher-Shahri AM, Samarghandian S. The role of curcumin in aging and senescence: Molecular mechanisms. Biomed Pharmacother [Internet]. 2021 Feb;134:111119. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0753332220313123 doi: 10.1016/j.biopha.2020.111119

Kocaadam B, Şanlier N. Curcumin, an active component of turmeric ( Curcuma longa ), and its effects on health. Crit Rev Food Sci Nutr [Internet]. 2017 Sep 2;57(13):2889–95. Available from: https://www.tandfonline.com/doi/full/10.1080/10408398.2015.1077195 doi: 10.1080/10408398.2015.1077195

Zhang T, Li Y, Song Y, Chen X, Li J, Peng Q, et al. Curcumin- and Cyclopamine-Loaded Liposomes to Enhance Therapeutic Efficacy Against Hepatic Fibrosis. Drug Des Devel Ther [Internet]. 2020 Dec;Volume 14:5667–78. Available from: https://www.dovepress.com/curcumin--and-cyclopamine-loaded-liposomes-to-enhance-therapeutic-effi-peer-reviewed-article-DDDT doi: 10.2147/DDDT.S287442

Qiu B, Xu X, Yi P, Hao Y. Curcumin reinforces MSC‐derived exosomes in attenuating osteoarthritis via modulating the miR‐124/NF‐kB and miR‐143/ROCK1/TLR9 signalling pathways. J Cell Mol Med [Internet]. 2020 Sep 9;24(18):10855–65. Available from: https://onlinelibrary.wiley.com/doi/10.1111/jcmm.15714 doi: 10.1111/jcmm.15714

Ghasemi F, Shafiee M, Banikazemi Z, Pourhanifeh MH, Khanbabaei H, Shamshirian A, et al. Curcumin inhibits NF-kB and Wnt/β-catenin pathways in cervical cancer cells. Pathol - Res Pract [Internet]. 2019 Oct;215(10):152556. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0344033819308830 doi: 10.1016/j.prp.2019.152556

Nouri-Vaskeh M, Malek Mahdavi A, Afshan H, Alizadeh L, Zarei M. Effect of curcumin supplementation on disease severity in patients with liver cirrhosis: A randomized controlled trial. Phyther Res. 2020;34(6):1446–54. https://doi.org/10.1002/ptr.6620

Nouri-Vaskeh M, Afshan H, Malek Mahdavi A, Alizadeh L, Fan X, Zarei M. Curcumin ameliorates health-related quality of life in patients with liver cirrhosis: A randomized, double-blind placebo-controlled trial. Complement Ther Med [Internet]. 2020;49(February):102351. Available from: https://doi.org/10.1016/j.ctim.2020.102351 doi: 10.1016/j.ctim.2020.102351

Thongsri P, Pewkliang Y, Borwornpinyo S, Wongkajornsilp A, Hongeng S, Sa-ngiamsuntorn K. Curcumin inhibited hepatitis B viral entry through NTCP binding. Sci Rep [Internet]. 2021 Dec 27;11(1):19125. Available from: https://www.nature.com/articles/s41598-021-98243-x doi: 10.1038/s41598-021-98243-x

Khan H, Ullah H, Nabavi SM. Mechanistic insights of hepatoprotective effects of curcumin: Therapeutic updates and future prospects. Food Chem Toxicol [Internet]. 2019 Feb;124:182–91. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0278691518308664 doi: 10.1016/j.fct.2018.12.002

Hernández-Aquino E, Quezada-Ramírez MA, Silva-Olivares A, Ramos-Tovar E, Flores-Beltrán RE, Segovia J, et al. Curcumin downregulates Smad pathways and reduces hepatic stellate cells activation in experimental fibrosis. Ann Hepatol [Internet]. 2020 Sep;19(5):497–506. Available from: https://linkinghub.elsevier.com/retrieve/pii/S166526812030065X doi: 10.1016/j.aohep.2020.05.006

Kapelle IBD, Manalu W, Souhoka FA. Effect of curcumin analogue synthetic product from cullilawan oil for the liver damage treatment in male mice (Mus musculus L.). J Basic Clin Physiol Pharmacol [Internet]. 2020 Jan 23;30(6). Available from: https://www.degruyter.com/document/doi/10.1515/jbcpp-2019-0241/html doi: 10.1515/jbcpp-2019-0241

Heshmati J, Golab F, Morvaridzadeh M, Potter E, Akbari-Fakhrabadi M, Farsi F, et al. The effects of curcumin supplementation on oxidative stress, Sirtuin-1 and peroxisome proliferator activated receptor γ coactivator 1α gene expression in polycystic ovarian syndrome (PCOS) patients: A randomized placebo-controlled clinical trial. Diabetes Metab Syndr Clin Res Rev [Internet]. 2020 Mar;14(2):77–82. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1871402120300035 doi: 10.1016/j.dsx.2020.01.002

Mouler Rechtman M, Har-Noy O, Bar-Yishay I, Fishman S, Adamovich Y, Shaul Y, et al. Curcumin inhibits hepatitis B virus via down-regulation of the metabolic coactivator PGC-1α. FEBS Lett [Internet]. 2010 Jun 3;584(11):2485–90. Available from: http://doi.wiley.com/10.1016/j.febslet.2010.04.067 doi: 10.1016/j.febslet.2010.04.067

Published

2023-04-10

How to Cite

1.
Santosa WN, Aditya DMN. Meta-Analisis pengaruh faktor daya dukung etiologi sirosis terhadap keberhasilan curcumin sebagai terapi. Media ilmu kesehatan [Internet]. 2023 Apr. 10 [cited 2024 Dec. 21];11(3). Available from: https://ejournal.unjaya.ac.id/index.php/mik/article/view/785